Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravafenix vs Atorvastatin in Combined Dyslipidemia
NCT02166593Phase 3Completed
- Sponsor
- Yooyoung Pharmaceutical
- Start
- May 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pravastatin + fenofibrate in combined dyslipidemia (2 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoint: Percent change from baseline in Non-HDL-C at 8 weeks. Started May 2014; status: completed.
02
Drugs
pravastatin + fenofibrate
03
Conditions
combined dyslipidemia
Beyond the preview
Go deeper on NCT02166593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166593.